Relationship between CAG repeat length and late-stage outcomes in Huntington's disease

Neurology

Volumn 59, Issue 10, 2002, Pages 1622-1624

  Marder, K ^a   Sandler, S ^b   Lechich, A ^b   Klager, J ^b   Albert, S M ^a,c  

^a Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHROMOSOME SIZE; CLINICAL ARTICLE; ENERGY EXPENDITURE; FEMALE; HUMAN; HUNTINGTON CHOREA; LONG TERM CARE; MALE; NURSING HOME; ONSET AGE; OUTCOMES RESEARCH; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR BINDING; TRINUCLEOTIDE REPEAT; VOLUMETRY;

EID: 0037180419     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000035627.16789.23     Document Type: Article

References (10)

1. Feigin A, Kieburtz K, Bordwell K, et al. Functional decline in Huntington's disease. Mov Disord 1995;10:211-214.
2. Kieburtz K, MacDonald M, Shih C. Trinucleotide repeat length and progression of illness in Huntington's disease. J Med Genet 1994;31:872-874.
3. Kremer B, Clark C, Almquist E, et al. Influence of lamotrigine on progression of early Huntington disease: A randomized clinical trial. Neurology 1999;53:1000-1011.
4. Brandt J, Bylsma FW, Gross R, Stine OC, Ranen N, Ross CA. Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology 1996;46:527-531.
5. Myers RH, Sax DS, Koroshetz WJ, et al. Factors associated with slow disease progression in Huntington's disease. Arch Neurol 1991;448:800-804.
6. Illarioshkin SN, Igarashi S, Onodera O, et al. Trinucleotide repeat length and rate of progression of Huntington's disease. Ann Neurol 1994;36:630-635.
7. Aylward EH, Li Q, Stine OC, et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997;48:394-399.
8. 11C]raclopride-PET studies of Huntington's disease rate of progression: Relevance of the trinucleotide repeat length. Ann Neurol 1998;43:253-255.
9. Furtado S, Suchowersky O, Rewcastle B, Graham L, Klimek M, Garber A. Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Ann Neurol 1996;39:132-136.
10. Penney JB, Vonsattel JP, MacDonald M, Gusella J, Myers R. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41:689-692.